Low doses of ketazolam in <font color="red">anxiety_2</font> <font color="red">:_2</font> a double - blind , placebo - controlled study . 
<br>
<br> <font color="red">A_1</font> <font color="red">multicenter_1</font> <font color="red">,_1</font> <font color="red">double_1</font> <font color="red">-_1</font> <font color="red">blind_1</font> <font color="red">,_1</font> <font color="red">between_1</font> <font color="red">-_1</font> <font color="red">patient_1</font> <font color="red">trial_1</font> <font color="red">comparing_1</font> <font color="red">two_1</font> <font color="red">doses_1</font> <font color="red">of_1</font> <font color="red">ketazolam_1</font> <font color="red">(_1</font> <font color="red">15_1</font> <font color="red">and_1</font> <font color="red">30_1</font> <font color="red">mg_1</font> <font color="red">)_1</font> <font color="red">with_1</font> <font color="red">placebo_1</font> <font color="red">,_1</font> <font color="red">each_1</font> <font color="red">given_1</font> <font color="red">once_1</font> <font color="red">daily_1</font> <font color="red">,_1</font> <font color="red">in_1</font> <font color="red">the_1</font> <font color="red">evening_1</font> <font color="red">,_1</font> <font color="red">to_1</font> <font color="red">92_6</font> <font color="red">outpatients_6</font> <font color="red">affected_6</font> <font color="red">by_6</font> <font color="red">generalized_6</font> <font color="red">anxiety_6</font> <font color="red">disorders_6</font> <font color="red">for_5</font> <font color="red">at_5</font> <font color="red">least_5</font> <font color="red">1_5</font> <font color="red">month_5</font> <font color="red">,_5</font> was carried out . After 1-week washout period <font color="red">47_2</font> <font color="red">patients_2</font> <font color="red">were_1</font> <font color="red">randomized_1</font> <font color="red">to_1</font> <font color="red">ketazolam_1</font> <font color="red">15_1</font> <font color="red">mg_1</font> <font color="red">,_1</font> <font color="red">and_1</font> <font color="red">45_1</font> <font color="red">to_1</font> <font color="red">placebo_1</font> for 15 days ( first period ) . At the end of this period , if the patient experienced a decrease on the total Hamilton Anxiety Rating Scale ( HAM - A ) of at least 25% of basal value , the treatment was kept unchanged for a further 15 days , otherwise 15 mg of ketazolam were added to the previous treatment ( second period ) . Anxiety was rated after 2 and 4 weeks with the Italian HAM - A scale and with a 4-point scale ( patient 's assessment ) . <font color="red">Seventy_3</font> <font color="red">-_3</font> <font color="red">eight_3</font> <font color="red">patients_3</font> <font color="red">completed_2</font> <font color="red">the_2</font> <font color="red">first_2</font> <font color="red">period_2</font> <font color="red">and_2</font> <font color="red">75_2</font> <font color="red">the_2</font> <font color="red">whole_2</font> <font color="red">study_2</font> <font color="red">._2</font> During the first period the percentage of responders was almost identical in both treatment groups , but during the second period a further slight improvement was observed in the early placebo responders , while the HAM - A score of patients on ketazolam continued to improve significantly ( p less than 0.01 ) throughout the study . Likewise a significant ( p less than 0.001 ) difference between treatments was observed , on the 4-point scale , in the population as a whole ( end of first period ) as well as in responder patients ( end second period ) . Tolerability was good , except in 1 patient on placebo , who was withdrawn from the study because of severe headache .